Hubbry Logo
FolateFolateMain
Open search
Folate
Community hub
Folate
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Folate
Folate
from Wikipedia

Folic acid
Skeletal formula
Clinical data
Pronunciation/ˈflɪk, ˈfɒlɪk/
Trade namesFolicet, Folvite
Other namesWills factor, FA, N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid, pteroyl-L-glutamic acid, folacin, vitamin B9;[1] formerly, vitamin Bc and vitamin M[2]
AHFS/Drugs.comMonograph
MedlinePlusa682591
License data
Pregnancy
category
  • AU: A
Routes of
administration
By mouth, intramuscular, intravenous, subcutaneous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only) / S2
  • US: ℞-only / OTC
Pharmacokinetic data
Bioavailability50–100%[3]
MetabolismLiver[3]
ExcretionUrine[3]
Identifiers
  • (2S)-2-[[4-[(2-Amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid[4]
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.000.381 Edit this at Wikidata
Chemical and physical data
FormulaC19H19N7O6
Molar mass441.404 g·mol−1
3D model (JSmol)
Density1.6±0.1 g/cm3 [5]
Melting point250 °C (482 °F) (decomposition)
Solubility in water1.6mg/L (25 °C)[5]
  • n1c2C(=O)NC(N)=Nc2ncc1CNc3ccc(cc3)C(=O)N[C@H](C(O)=O)CCC(O)=O
  • InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1
  • Key:OVBPIULPVIDEAO-LBPRGKRZSA-N

Folate, also known as vitamin B9 and folacin,[6] is one of the B vitamins.[1][3] Manufactured folic acid, which is converted into folate by the body, is used as a dietary supplement and in food fortification as it is more stable during processing and storage.[1][6] Folate is required for the body to make DNA and RNA and metabolise amino acids necessary for cell division and maturation of blood cells.[1][7] As the human body cannot make folate, it is required in the diet, making it an essential nutrient.[8] It occurs naturally in many foods.[1][6] The recommended adult daily intake of folate in the U.S. is 400 micrograms from foods or dietary supplements.[1]

Folate in the form of folic acid is used to treat anemia caused by folate deficiency.[3] Folic acid is also used as a supplement by women during pregnancy to reduce the risk of neural tube defects (NTDs) in the baby.[3][9] NTDs include anencephaly and spina bifida, among other defects. Low levels in early pregnancy are believed to be the cause of more than half of babies born with NTDs.[1] More than 80 countries use either mandatory or voluntary fortification of certain foods with folic acid as a measure to decrease the rate of NTDs.[10] Long-term supplementation with relatively large amounts of folic acid is associated with a small reduction in the risk of stroke[11] and an increased risk of prostate cancer.[12].

Not consuming enough folate can lead to folate deficiency.[1] This may result in a type of anemia in which red blood cells become abnormally large.[1] Symptoms may include feeling tired, heart palpitations, shortness of breath, open sores on the tongue, and changes in the color of the skin or hair.[1] Folate deficiency in children may develop within a month of poor dietary intake.[13] In adults, normal total body folate is between 10 and 30 mg with about half of this amount stored in the liver and the remainder in blood and body tissues.[1] In plasma, the natural folate range is 150 to 450 nM.[14]

Folate was discovered between 1931 and 1943.[15] It is on the World Health Organization's List of Essential Medicines.[16] In 2023, it was the 94th most commonly prescribed medication in the United States, with more than 7 million prescriptions.[17][18] The term "folic" is from the Latin word folium (which means leaf) because it was found in dark-green leafy vegetables.[19]

Definition

[edit]
Chemical structure of the folate family

Folate (vitamin B9) refers to the many forms of folic acid and its related compounds, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid, folacin, and pteroylglutamic acid.[6][20][21][22] Historic names included L. ⁠casei factor, vitamin Bc and vitamin M.[2]

The terms folate and folic acid have somewhat different meanings in different contexts, although sometimes used interchangeably.[23] Within the field of organic chemistry, folate refers to the conjugate base of folic acid.[24][22] Within the field of biochemistry, folates refer to a class of biologically active compounds related to and including folic acid.[25] Within the field of nutrition, the folates are a family of essential nutrients related to folic acid obtained from natural sources whereas the term folic acid is reserved for the manufactured form that is used as a dietary supplement.[26]

Chemically, folates consist of three distinct chemical moieties linked together. A pterin (2-amino-4-hydroxy-pteridine) heterocyclic ring is linked by a methylene bridge to a p-aminobenzoyl group that in turn is bonded through an amide linkage to either glutamic acid or poly-glutamate. One-carbon units in a variety of oxidation states may be attached to the N5 nitrogen atom of the pteridine ring and/or the N10 nitrogen atom of the p-aminobenzoyl group.[27]

Health effects

[edit]

Folate is especially important during periods of frequent cell division and growth, such as infancy and pregnancy. Folate deficiency hinders DNA synthesis and cell division, affecting hematopoietic cells and neoplasms the most because of their greater frequency of cell division. RNA transcription and subsequent protein synthesis are less affected by folate deficiency, as the mRNA can be recycled and used again (as opposed to DNA synthesis, where a new genomic copy must be created).

Birth defects

[edit]

Deficiency of folate in pregnant women has been implicated in neural tube defects (NTDs), with an estimate of 300,000 cases worldwide prior to the implementation in many countries of mandatory food fortification.[28] NTDs occur early in pregnancy (first month), therefore women must have abundant folate upon conception and for this reason there is a recommendation that any woman planning to become pregnant consume a folate-containing dietary supplement before and during pregnancy.[29] The Center for Disease Control and Prevention (CDC) recommends a daily amount of 400 micrograms of folic acid for the prevention of NTDs.[30] Many women take this medication less than the CDC recommends, especially in cases where the pregnancy was unplanned, or in countries that lack healthcare resources and education. Some countries have implemented either mandatory or voluntary food fortification of wheat flour and other grains,[31] but many others rely on public health education and one-on-one healthcare practitioner advice. A meta-analysis of global birth prevalence of spina bifida showed that when a national, mandatory program to fortify the diet with folate was compared to countries without such a fortification program, there was a 30% reduction in live births with spina bifida.[32] Some countries reported a greater than 50% reduction.[33] The United States Preventive Services Task Force recommends folic acid as the supplement or fortification ingredient, as forms of folate other than folic acid have not been studied.[21]

A meta-analysis of folate supplementation during pregnancy reported a 28% lower relative risk of newborn congenital heart defects.[34] Prenatal supplementation with folic acid did not appear to reduce the risk of preterm births.[35][36] One systematic review indicated no effect of folic acid on mortality, growth, body composition, respiratory, or cognitive outcomes of children from birth to 9 years old.[37] There was no relation between maternal folic acid supplementation and an increased risk for childhood asthma.[38]

Fertility

[edit]

Folate contributes to spermatogenesis.[39] In women, folate is important for oocyte quality and maturation, implantation, placentation, fetal growth and organ development.[39]

Heart disease

[edit]

One meta-analysis reported that multi-year folic acid supplementation, in amounts in most of the included clinical trials at higher than the upper limit of 1,000 μg/day, reduced the relative risk of cardiovascular disease by a modest 4%.[11] Two older meta-analyses, which would not have incorporated results from newer clinical trials, reported no changes to the risk of cardiovascular disease.[40][41]

Stroke

[edit]

The absolute risk of stroke with supplementation decreases from 4.4% to 3.8% (a 10% decrease in relative risk).[11] Two other meta-analyses reported a similar decrease in relative risk.[42][43] Two of these three were limited to people with pre-existing cardiovascular disease or coronary heart disease.[11][42] The beneficial result may be associated with lowering circulating homocysteine concentration, as stratified analysis showed that risk was reduced more when there was a larger decrease in homocysteine.[11][42] The effect was also larger for the studies that were conducted in countries that did not have mandatory grain folic acid fortification.[42][43] The beneficial effect was larger in the subset of trials that used a lower folic acid supplement compared to higher.[42][43]

Cancer

[edit]

Chronically insufficient intake of folate may increase the risk of colorectal, breast, ovarian, pancreatic, brain, lung, cervical, prostate, oesophageal, oral and pharyngeal cancers.[6][44][45] [46]

Higher intake of folate from foods has been associated with reducing the adverse effects of alcohol on breast cancer risk.[47]

Due to the risks associated with folate deficiency, folic acid fortification of foods was initiated. Shortly after folic acid fortification was introduced, concerns were raised that higher intake might promote the progression of preneoplastic lesions in the colon (early cellular changes that could become cancer).[48][49]

Subsequent meta-analyses of the effects of low versus high dietary folate, elevated serum folate, and folic acid supplementation have reported conflicting results. One study that compared low to high dietary folate showed a modest but statistically significant reduction in colon cancer risk.[50]

  • Another study that also compared low to high dietary folate showed no effect on the risk for prostate cancer, .[51][52] In contrast, a review of trials involving folic acid dietary supplements reported a statistically significant 24% increase in prostate cancer risk.[12] Supplementation in these trials typically used 1,000 to 2,500 μg/day of folic acid[12][53]—higher than what is achieved through diets rich in naturally occurring folate. Another supplementation review reported no significant increase or decrease in total cancer incidence, colorectal cancer, other gastrointestinal cancer, genitourinary cancer, lung cancer or hematological malignancies among people who consumed folic acid supplements.[53] Another supplementation meta-analysis limited to colorectal cancer showed that folic acid supplementation was not associated with colorectal cancer risk.[54]

Taken together, the evidence indicates that higher dietary folate intake may be associated with reduced colorectal cancer risk, while results for high-dose folic acid supplementation are inconsistent — with some studies showing no effect and others reporting a possible increased risk for prostate cancer — suggesting that effects may vary by cancer type.

Anti-folate chemotherapy

[edit]

Folate is important for cells and tissues that divide rapidly.[55] Cancer cells divide rapidly, and drugs that interfere with folate metabolism are used to treat cancer. The antifolate drug methotrexate is often used to treat cancer because it inhibits the production of the active tetrahydrofolate (THF) from the inactive dihydrofolate (DHF).[56] However, methotrexate can be toxic,[57][58][59] producing side effects such as inflammation in the digestive tract that make eating normally more difficult. Bone marrow depression (inducing leukopenia and thrombocytopenia) and acute kidney and liver failure have been reported.

Folinic acid, under the drug name leucovorin, a form of folate (formyl-THF), can help "rescue" or reverse the toxic effects of methotrexate.[60] Folic acid supplements have little established role in cancer chemotherapy.[61][62] The supplement of folinic acid in people undergoing methotrexate treatment is to give less rapidly dividing cells enough folate to maintain normal cell functions. The amount of folate given is quickly depleted by rapidly dividing (cancer) cells, so this does not negate the effects of methotrexate.

Neurological disorders

[edit]

Conversion of homocysteine to methionine requires folate and vitamin B12. Elevated plasma homocysteine and low folate are associated with cognitive impairment, dementia and Alzheimer's disease.[63][64] Supplementing the diet with folic acid and vitamin B12 lowers plasma homocysteine.[64] However, several reviews reported that supplementation with folic acid alone or in combination with other B vitamins did not prevent development of cognitive impairment nor slow cognitive decline.[65][64][66]

Maternal folic acid supplementation during pregnancy is associated with a reduced risk of autism in children across Asian, European, and American populations.[67] Cerebral folate deficiency, often caused by folate receptor alpha autoantibodies, is common in autism. Treatment with folinic acid appears to be safe, and one meta review found that, in children, it may produduce a minor-to-significant improvement in symptoms stereotypically associated with ASD.[68]

Some evidence links a shortage of folate with clinical depression.[69] An 2024 umbrella meta-analysis concluded that folate supplementation alleviates depression symptoms, while folate deficiency is associated with an increased risk of depression, suggesting folate as a beneficial adjunctive treatment in managing depression.[70] Other research also found a link between depression and low levels of folate.[71][72] The exact mechanisms involved in the development of schizophrenia and depression are not entirely clear, but the bioactive folate, methyltetrahydrofolate (5-MTHF), a direct target of methyl donors such as S-adenosyl methionine (SAMe), recycles the inactive dihydrobiopterin (BH2) into tetrahydrobiopterin (BH4), the necessary cofactor in various steps of monoamine synthesis, including that of dopamine and serotonin. BH4 serves a regulatory role in monoamine neurotransmission and is required to mediate the actions of most antidepressants.[73]

Folic acid, B12 and iron

[edit]

A complex interaction occurs between folic acid, vitamin B12, and iron. A deficiency of folic acid or vitamin B12 may mask the deficiency of iron; so when taken as dietary supplements, the three need to be in balance.[74][75][76]

Malaria

[edit]

Some studies show iron–folic acid supplementation in children under five may result in increased mortality due to malaria; this has prompted the World Health Organization to alter their iron–folic acid supplementation policies for children in malaria-prone areas, such as India.[77]

Absorption, metabolism and excretion

[edit]

Folate in food is roughly one-third in the form of monoglutamate and two-thirds polyglutamate; the latter is hydrolyzed to monoglutamate via a reaction mediated by folate conjugase at the brush border of enterocytes in the proximal small intestine.[78] Subsequently, intestinal absorption is primarily accomplished by the action of the proton-coupled folate transporter (PCFT) protein coded for by the SLC46A1 gene. This functions best at pH 5.5, which corresponds to the acidic status of the proximal small intestine. PCFT binds to both reduced folates and folic acid. A secondary folate transporter is the reduced folate carrier (RFC), coded for by the SLC19A1 gene. It operates optimally at pH 7.4 in the ileum portion of the small intestine. It has a low affinity for folic acid. Production of the receptor proteins is increased in times of folate deficiency.[79] In addition to a role in intestinal absorption, RFC is expressed in virtually all tissues and is the major route of delivery of folate to cells within the systemic circulation under physiological conditions. When pharmacological amounts of folate are taken as a dietary supplement, absorption also takes place by a passive diffusion-like process.[7][80] In addition, bacteria in the distal portion of the small intestine and in the large intestine synthesize modest amounts of folate, and there are RFC receptors in the large intestine, so this in situ source may contribute to toward the cellular nutrition and health of the local colonocytes.[79][80]

The biological activity of folate in the body depends upon dihydrofolate reductase action in the liver which converts folate into tetrahydrofolate (THF). This action is rate-limiting in humans leading to elevated blood concentrations of unmetabolized folic acid when consumption from dietary supplements and fortified foods nears or exceeds the U.S. Tolerable Upper Intake Level of 1,000 μg per day.[7][81]

The total human body content of folate is estimated to be approximately 15–30 milligrams, with approximately half in the liver.[7] Excretion is via urine and feces. Under normal dietary intake, urinary excretion is mainly as folate cleavage products, but if a dietary supplement is being consumed then there will be intact folate in the urine. The liver produces folate-containing bile, which if not all absorbed in the small intestine, contributes to fecal folate, intact and as cleavage products, which under normal dietary intake has been estimated to be similar in amount to urinary excretion. Fecal content includes what is synthesized by intestinal microflora.[7]

Biosynthesis

[edit]

Animals, including humans, cannot synthesize (produce) folate and therefore must obtain folate from their diet. All plants and fungi and certain protozoa, bacteria, and archaea can synthesize folate de novo through variations on the same biosynthetic pathway.[82] The folate molecule is synthesized from pterin pyrophosphate, para-aminobenzoic acid (PABA), and glutamate through the action of dihydropteroate synthase and dihydrofolate synthase. Pterin is in turn derived in a series of enzymatically catalyzed steps from guanosine triphosphate (GTP), while PABA is a product of the shikimate pathway.[82]

Bioactivation

[edit]
Biotransformation of folic acid into folinic acids where R = para-aminobenzoate-glutamate[83]

All of the biological functions of folic acid are performed by THF and its methylated derivatives. Hence folic acid must first be reduced to THF. This four electron reduction proceeds in two chemical steps both catalyzed by the same enzyme, dihydrofolate reductase.[83] Folic acid is first reduced to dihydrofolate and then to tetrahydrofolate. Each step consumes one molecule of NADPH (biosynthetically derived from vitamin B3) and produces one molecule of NADP.[7][84] Mechanistically, hydride is transferred from NADPH to the C6 position of the pteridine ring.[85]

A one-carbon (1C) methyl group is added to tetrahydrofolate through the action of serine hydroxymethyltransferase (SHMT) to yield 5,10-methylenetetrahydrofolate (5,10-CH2-THF). This reaction also consumes serine and pyridoxal phosphate (PLP; vitamin B6) and produces glycine and pyridoxal.[83] A second enzyme, methylenetetrahydrofolate dehydrogenase (MTHFD2)[86] oxidizes 5,10-methylenetetrahydrofolate to an iminium cation which in turn is hydrolyzed to produce 5-formyl-THF and 10-formyl-THF.[83] This series of reactions using the β-carbon atom of serine as the carbon source provide the largest part of the one-carbon units available to the cell.[87]

Alternative carbon sources include formate which by the catalytic action of formate–tetrahydrofolate ligase adds a 1C unit to THF to yield 10-formyl-THF. Glycine, histidine, and sarcosine can also directly contribute to the THF-bound 1C pool.[88]

Drug interference

[edit]

A number of drugs interfere with the biosynthesis of THF from folic acid. Among them are the antifolate dihydrofolate reductase inhibitors such as the antimicrobial, trimethoprim, the antiprotozoal, pyrimethamine and the chemotherapy drug methotrexate,[89][90] and the sulfonamides (competitive inhibitors of PABA in the reactions of dihydropteroate synthetase).[91]

Valproic acid, one of the most commonly prescribed epilepsy treatment drugs, also used to treat certain psychological conditions such as bipolar disorder, is a known inhibitor of folic acid, and as such, has been shown to cause birth defects, including neural tube defects, plus increased risk for children having cognitive impairment and autism. There is evidence that folate consumption is protective.[92][93][94]

Folate deficiency is common in alcoholics, attributed to both inadequate diet and an inhibition in intestinal processing of the vitamin. Chronic alcohol use inhibits both the digestion process of dietary folate polyglutamates and the uptake phase of liberated folate monoglutamates. The latter is associated with a significant reduction in the level of expression of RFC.[79]

Function

[edit]

Tetrahydrofolate's main function in metabolism is transporting single-carbon groups (i.e., a methyl group, methylene group, or formyl group). These carbon groups can be transferred to other molecules as part of the modification or biosynthesis of a variety of biological molecules. Folates are essential for the synthesis of DNA, the modification of DNA and RNA, the synthesis of methionine from homocysteine, and various other chemical reactions involved in cellular metabolism.[95] These reactions are collectively known as folate-mediated one-carbon metabolism.[7][96]

DNA synthesis

[edit]

Folate derivatives participate in the biosynthesis of both purines and pyrimidines.

Formyl folate is required for two of the steps in the biosynthesis of inosine monophosphate, the precursor to GMP and AMP. Methylenetetrahydrofolate donates the C1 center required for the biosynthesis of dTMP (2-deoxythymidine-5-phosphate) from dUMP (2-deoxyuridine-5-phosphate). The conversion is catalyzed by thymidylate synthase.[7]

Vitamin B12 activation

[edit]
Simplified schematic diagram of the folate methionine cycle[97]

Methyl-THF converts vitamin B12 to methyl-B12 (methylcobalamin). Methyl-B12 converts homocysteine, in a reaction catalyzed by homocysteine methyltransferase, to methionine. A defect in homocysteine methyltransferase or a deficiency of B12 may lead to a so-called "methyl-trap" of THF, in which THF converts to methyl-THF, causing a deficiency in folate.[98] Thus, a deficiency in B12 can cause accumulation of methyl-THF, mimicking folate deficiency.

Dietary recommendations

[edit]

Because of the difference in bioavailability between supplemented folic acid and the different forms of folate found in food, the dietary folate equivalent (DFE) system was established. One DFE is defined as 1 μg of dietary folate. 1 μg of folic acid supplement counts as 1.7 μg DFE. The reason for the difference is that when folic acid is added to food or taken as a dietary supplement with food it is at least 85% absorbed, whereas only about 50% of folate naturally present in food is absorbed.[1]

National Institutes of Health (U.S.) nutritional recommendations[1]
μg DFE per day for RDA, μg folic acid for tolerable upper intake levels (UL)
Age Infants Children and adults Pregnant women Lactating women
(AI) (UL) (RDA) (UL) (RDA) (UL) (RDA) (UL)
0–6 months 65 None set
7–12 months 80 None set
1–3 years 150 300
4–8 years 200 400  –
9–13 years 300 600
14–18 400 800 600 800 500 800
19+ 400 1000 600 1000 500 1000

The U.S. Institute of Medicine defines Estimated Average Requirements (EARs), Recommended Dietary Allowances (RDAs), Adequate Intakes (AIs), and Tolerable upper intake levels (ULs) – collectively referred to as Dietary Reference Intakes (DRIs).[1][99] The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL are defined the same as in the United States. For women and men over age 18, the PRI is set at 330 μg/day. PRI for pregnancy is 600 μg/day, for lactation 500 μg/day. For children ages 1–17 years, the PRIs increase with age from 120 to 270 μg/day. These values differ somewhat from the U.S. RDAs.[100] The United Kingdom's Dietary Reference Value for folate, set by the Committee on Medical Aspects of Food and Nutrition Policy in 1991, is 200 μg/day for adults.[101]

Safety

[edit]

The risk of toxicity from folic acid is low because folate is a water-soluble vitamin and is regularly removed from the body through urine. One potential issue associated with high doses of folic acid is that it has a masking effect on the diagnosis of pernicious anaemia due to vitamin B12 deficiency, and may even precipitate or exacerbate neuropathy in vitamin B12-deficient individuals. This evidence justified development of a UL for folate.[99] In general, ULs are set for vitamins and minerals when evidence is sufficient. The adult UL of 1,000 μg for folate (and lower for children) refers specifically to folic acid used as a supplement, as no health risks have been associated with high intake of folate from food sources. The EFSA reviewed the safety question and agreed with United States that the UL be set at 1,000 μg.[102] The Japan National Institute of Health and Nutrition set the adult UL at 1,300 or 1,400 μg depending on age.[103]

Reviews of clinical trials that called for long-term consumption of folic acid in amounts exceeding the UL have raised concerns. Excessive amounts derived from supplements are more of a concern than that derived from natural food sources and the relative proportion to vitamin B12 may be a significant factor in adverse effects.[104] One theory is that consumption of large amounts of folic acid leads to detectable amounts of unmetabolized folic acid circulating in blood because the enzyme dihydrofolate reductase that converts folic acid to the biologically active forms is rate limiting. Evidence of a negative health effect of folic acid in blood is not consistent, and folic acid has no known cofactor function that would increase the likelihood of a causal role for free folic acid in disease development.[105] Long-term use of folic acid dietary supplements in excess of 1,000 μg/day has been linked to an increase in prostate cancer risk.[12]

Food labeling

[edit]

For U.S. food and dietary supplement labeling purposes, the amount in a serving is expressed as a percent of Daily Value (%DV). For folate labeling purposes, 100% of the Daily Value was 400 μg. As of the 27 May 2016 update, it was kept unchanged at 400 μg.[106][107] Compliance with the updated labeling regulations was required by 1 January 2020 for manufacturers with US$10 million or more in annual food sales, and by 1 January 2021 for manufacturers with lower volume food sales.[108][109] A table of the old and new adult daily values is provided at Reference Daily Intake.

European Union regulations require that labels declare energy, protein, fat, saturated fat, carbohydrates, sugars, and salt. Voluntary nutrients may be shown if present in significant amounts. Instead of Daily Values, amounts are shown as percent of Reference Intakes (RIs). For folate, 100% RI was set at 200 μg in 2011.[110]

Deficiency

[edit]

Folate deficiency can be caused by unhealthy diets that do not include enough vegetables and other folate-rich foods; diseases in which folates are not well absorbed in the digestive system (such as Crohn's disease or celiac disease); some genetic disorders that affect levels of folate; and certain medicines (such as phenytoin, sulfasalazine, or trimethoprim-sulfamethoxazole).[111] Folate deficiency is accelerated by alcohol consumption, possibly by interference with folate transport.[112]

Folate deficiency may lead to glossitis, diarrhea, depression, confusion, anemia, and fetal neural tube and brain defects.[99] Other symptoms include fatigue, gray hair, mouth sores, poor growth, and swollen tongue.[111] Folate deficiency is diagnosed by analyzing a complete blood count (CBC) and plasma vitamin B12 and folate levels. A serum folate of 3 μg/L or lower indicates deficiency.[99] Serum folate level reflects folate status, but erythrocyte folate level better reflects tissue stores after intake. An erythrocyte folate level of 140 μg/L or lower indicates inadequate folate status. Serum folate reacts more rapidly to folate intake than erythrocyte folate.[113]

Since folate deficiency limits cell division, erythropoiesis (production of red blood cells) is hindered. This leads to megaloblastic anemia, which is characterized by large, immature red blood cells. This pathology results from persistently thwarted attempts at normal DNA replication, DNA repair, and cell division, and produces abnormally large red cells called megaloblasts (and hypersegmented neutrophils) with abundant cytoplasm capable of RNA and protein synthesis, but with clumping and fragmentation of nuclear chromatin. Some of these large cells, although immature (reticulocytes), are released early from the marrow in an attempt to compensate for the anemia.[114] Both adults and children need folate to make normal red and white blood cells and prevent anemia, which causes fatigue, weakness, and inability to concentrate.[115][116]

Increased homocysteine levels suggest tissue folate deficiency, but homocysteine is also affected by vitamin B12 and vitamin B6, renal function, and genetics. One way to differentiate between folate deficiency and vitamin B12 deficiency is by testing for methylmalonic acid (MMA) levels. Normal MMA levels indicate folate deficiency and elevated MMA levels indicate vitamin B12 deficiency.[99] Elevated MMA levels may also be due to the rare metabolic disorder combined malonic and methylmalonic aciduria (CMAMMA).[117][118]

Folate deficiency is treated with supplemental oral folic acid of 400 to 1000 μg per day. This treatment is very successful in replenishing tissues, even if deficiency was caused by malabsorption. People with megaloblastic anemia need to be tested for vitamin B12 deficiency before treatment with folic acid, because if the person has vitamin B12 deficiency, folic acid supplementation can remove the anemia, but can also worsen neurologic problems.[99] Cobalamin (vitamin B12) deficiency may lead to folate deficiency, which, in turn, increases homocysteine levels and may result in the development of cardiovascular disease or birth defects.[119]

Sources

[edit]

The United States Department of Agriculture, Agricultural Research Service maintains a food composition database from which folate content in hundreds of foods can be searched as shown in the table.[120] The Food Fortification Initiative lists all countries in the world that conduct fortification programs,[121] and within each country, what nutrients are added to which foods, and whether those programs are voluntary or mandatory. In the US, mandatory fortification of enriched breads, cereals, flours, corn meal, pastas, rice, and other grain products began in January 1998. As of 2023, 140 countries require food fortification with one or more vitamins,[31] with folate required in 69 countries. The most commonly fortified food is wheat flour, followed by maize flour and rice. From country to country, added folic acid amounts range from 0.4 to 5.1 mg/kg, but the great majority are in a more narrow range of 1.0 to 2.5 mg/kg, i.e. 100–250 μg/100g.[31] Folate naturally found in food is susceptible to destruction from high heat cooking, especially in the presence of acidic foods and sauces. It is soluble in water, and so may be lost from foods boiled in water.[122] For foods that are normally consumed cooked, values in the table are for folate naturally occurring in cooked foods.

Plant sources[120] Amount as
Folate
(μg / 100 g)
Peanuts 246
Sunflower seed kernels 238
Lentils 181
Chickpeas 172
Asparagus 149
Spinach 146
Lettuce 136
Peanuts (oil-roasted) 125
Soybeans 111
Broccoli 108
Walnuts 98
Plant sources[120] Amount as
Folate
(μg / 100 g)
Peanut butter 92
Hazelnuts 88
Avocados 81
Beets 80
Kale 65
Bread (not fortified) 65
Cabbage 46
Red bell peppers 46
Cauliflower 44
Tofu 29
Potatoes 28
Animal sources[120] Amount as
Folate
(μg / 100 g)
Chicken liver 578
Calf liver 331
Cheese 20–60
Chicken eggs 44
Salmon 35
Chicken 12
Beef 12
Pork 8
Yogurt 8–11
Milk, whole 5
Butter, salted 3

Food fortification

[edit]

Folic acid fortification is a process where synthetic folic acid is added to wheat flour or other foods with the intention of promoting public health through increasing blood folate levels in the populace. It is used as it is more stable during processing and storage.[6][1] After the discovery of the link between insufficient folic acid and neural tube defects, governments and health organizations worldwide made recommendations concerning folic acid supplementation for women intending to become pregnant. Because the neural tube closes in the first four weeks of gestation, often before many women even know they are pregnant, many countries in time decided to implement mandatory food fortification programs. A meta-analysis of global birth prevalence of spina bifida showed that when mandatory fortification was compared to countries with voluntary fortification or no fortification program, there was a 30% reduction in live births with spina bifida,[32] with some countries reporting a greater than 50% reduction.[33]

Folic acid is added to grain products in more than 80 countries, either as required or voluntary fortification,[10][31] and these fortified products make up a significant source of the population's folate intake.[123] The Food Fortification Initiative lists all countries in the world that conduct fortification programs,[121] and within each country, what nutrients are added to which foods. As of Sep 2025, the Global Fortification Data Exchange reports that folate is a mandatory fortified vitamin in 70 countries, beat only by iodine at 126 and iron at 87; the most commonly fortified food by far is wheat flour.[31]

Australia and New Zealand

[edit]

Australia and New Zealand jointly agreed to wheat flour fortification through the Food Standards Australia New Zealand in 2007. The requirement was set at 135 μg of folate per 100 g of bread. Australia implemented the program in 2009.[124] New Zealand was also planning to fortify bread (excluding organic and unleavened varieties) starting in 2009, but then opted to wait until more research was done. The Association of Bakers and the Green Party had opposed mandatory fortification, describing it as "mass medication".[125][126] Food Safety Minister Kate Wilkinson reviewed the decision to fortify in July 2009, citing as reasons to oppose claims for links between over consumption of folate with increased risk of cancer.[127] In 2012 the delayed mandatory fortification program was revoked and replaced by a voluntary program, with the hope of achieving a 50% bread fortification target.[128]

Canada

[edit]

Canadian public health efforts focused on promoting awareness of the importance of folic acid supplementation for all women of childbearing age and decreasing socio-economic inequalities by providing practical folic acid support to vulnerable groups of women.[129] Folic acid food fortification became mandatory in 1998, with the fortification of 150 μg of folic acid per 100 grams of enriched flour and uncooked cereal grains.[49] The results of folic acid fortification on the rate of neural tube defects in Canada have been positive, showing a 46% reduction in prevalence of NTDs; the magnitude of reduction was proportional to the prefortification rate of NTDs, essentially removing geographical variations in rates of NTDs seen in Canada before fortification.[130]

United Kingdom

[edit]

While the Food Standards Agency recommended folic acid fortification,[131][132][133] and wheat flour is fortified with iron,[134] folic acid fortification of wheat flour is allowed voluntarily rather than required. A 2018 review by authors based in the United Kingdom strongly recommended that mandatory fortification be reconsidered as a means of reducing the risk of neural tube defects.[10] In November 2024 the UK government announced legislation to require folic acid fortification in bread by the end of 2026.[135]

United States

[edit]
In the United States and many other countries, wheat flour is fortified with folic acid; some countries also fortify maize flour and rice.[31]

In 1996, the United States Food and Drug Administration (FDA) published regulations requiring the addition of folic acid to enriched breads, cereals, flours, corn meals, pastas, rice, and other grain products.[136] This ruling took effect on 1 January 1998, and was specifically targeted to reduce the risk of neural tube birth defects in newborns.[137] There were concerns expressed that the amount of folate added was insufficient.[138]

The fortification program was expected to raise a person's folic acid intake level by 70–130 μg/day;[139] however, an increase of almost double that amount was actually observed.[140] This could be from the fact that many foods are fortified by 160–175% over the required amount.[140] Much of the elder population take supplements that add 400 μg to their daily folic acid intake. This is a concern because 70–80% of the population have detectable levels of unmetabolized folic acid in their blood, a consequence of folic acid supplementation and fortification.[48] However, at blood concentrations achieved via food fortification, folic acid has no known cofactor function that would increase the likelihood of a causal role for free folic acid in disease development.[105]

The U.S. National Center for Health Statistics conducts the biannual National Health and Nutrition Examination Survey (NHANES) to assess the health and nutritional status of adults and children in the United States. Some results are reported as What We Eat In America. The 2013–2014 survey reported that for adults ages 20 years and older, men consumed an average of 249 μg/day folate from food plus 207 μg/day of folic acid from consumption of fortified foods, for a combined total of 601 μg/day of dietary folate equivalents (DFEs because each microgram of folic acid counts as 1.7 μg of food folate). For women, the values are 199, 153 and 459 μg/day, respectively. This means that fortification led to a bigger increase in folic acid intake than first projected, and that more than half the adults are consuming more than the RDA of 400 μg (as DFEs). Even so, fewer than half of pregnant women are exceeding the pregnancy RDA of 600 μg/day.[141]

Before folic acid fortification, about 4,100 pregnancies were affected by a neural tube defect each year in the United States. The Centers for Disease Control and Prevention reported in 2015 that since the addition of folic acid in grain-based foods as mandated by the FDA, the rate of neural tube defects dropped by 35%. This translates to an annual saving in total direct costs of approximately $508 million for the NTD-affected births that were prevented.[142][143]

History

[edit]

In the 1920s, scientists believed folate deficiency and anemia were the same condition.[144] In 1931, researcher Lucy Wills made a key observation that led to the identification of folate as the nutrient required to prevent anemia during pregnancy. Wills demonstrated that anemia could be reversed with brewer's yeast.[15][145] In the late 1930s, folate was identified as the corrective substance in brewer's yeast. It was first isolated via extraction from spinach leaves by Herschel K. Mitchell, Esmond E. Snell, and Roger J. Williams in 1941.[146] The term "folic" is from the Latin word folium (which means leaf) because it was found in dark-green leafy vegetables.[19] Historic names included L. casei factor, vitamin Bc after research done in chicks and vitamin M after research done in monkeys.[2]

Bob Stokstad isolated the pure crystalline form in 1943, and was able to determine its chemical structure while working at the Lederle Laboratories of the American Cyanamid Company.[98] This historical research project, of obtaining folic acid in a pure crystalline form in 1945, was done by the team called the "folic acid boys", under the supervision and guidance of Director of Research Dr. Yellapragada Subbarow, at the Lederle Lab, Pearl River, New York.[147][148] This research subsequently led to the synthesis of the antifolate aminopterin, which was used to treat childhood leukemia by Sidney Farber in 1948.[98][149]

In the 1950s and 1960s, scientists began to discover the biochemical mechanisms of action for folate.[144] In 1960, researchers linked folate deficiency to risk of neural tube defects.[144] In the late 1990s, the U.S. and Canadian governments decided that despite public education programs and the availability of folic acid supplements, there was still a challenge for women of child-bearing age to meet the daily folate recommendations, which is when those two countries implemented folate fortification programs.[137] As of December 2018, 62 countries mandated food fortification with folic acid.[31]

Animals

[edit]

Veterinarians may test cats and dogs if a risk of folate deficiency is indicated. Cats with exocrine pancreatic insufficiency, more so than dogs, may have low serum folate. In dog breeds at risk for cleft lip and cleft palate dietary folic acid supplementation significantly decreased incidence.[150]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Folate, also known as vitamin B9, is a water-soluble B vitamin comprising a family of compounds essential for one-carbon transfer reactions involved in DNA and RNA synthesis, amino acid metabolism, and red blood cell formation. These functions underpin cellular division and maturation, with folate acting as a coenzyme in the form of tetrahydrofolate derivatives. Naturally occurring reduced folates differ from folic acid, the synthetic fully oxidized form used in supplements and fortification, which requires metabolic reduction to active forms via dihydrofolate reductase. Dietary sources of folate include leafy green vegetables, , nuts, and liver, though varies and is often lower than that of folic acid due to food matrix effects and polyglutamate structure requiring . The recommended dietary allowance for adults is 400 micrograms of dietary folate equivalents daily, increasing to 600 micrograms during to support fetal development and prevent defects. Deficiency manifests as from impaired , elevated levels, and heightened risk of congenital anomalies, with empirical data from fortification programs showing a 20-50% reduction in incidence post-implementation in countries like the since 1998. Folate's identification arose from early 20th-century investigations into s unresponsive to iron, with Lucy Wills demonstrating in the 1930s that yeast extracts cured tropical in pregnant women, leading to isolation of the "Wills factor" and synthesis of folic acid by 1945. While supplementation effectively addresses deficiency, polymorphisms in genes like MTHFR impair folic acid conversion in up to 40% of populations, potentially leading to unmetabolized accumulation and prompting debate on prioritizing natural folates or active forms like 5-methyltetrahydrofolate. strategies emphasize fortification's causal role in deficiency prevention, though excess intake risks masking and mixed evidence exists on long-term effects like modulation.

Definition and Chemistry

Chemical Structure and Properties

Folic acid, the fully oxidized synthetic form of folate (vitamin B9), features a core structure comprising a pteridine ring fused to para-aminobenzoic acid via a and linked to γ-L-glutamic acid through an amide bond, yielding the molecular formula C₁₉H₁₉N₇O₆ and a molecular weight of 441.40 g/mol. This monoglutamate configuration distinguishes it from natural folates, which retain the same pteroyl backbone but incorporate a reduced pteridine moiety (typically as tetrahydrofolate derivatives) and a conjugated polyglutamate chain of up to nine L-glutamic acid residues, enhancing tissue retention and enzymatic interactions. Folic acid exhibits low in (approximately 1.6 mg/L at 25°C), rendering it nearly insoluble in neutral aqueous media below 5, but solubility markedly increases in dilute acids (e.g., hydrochloric or ) or alkaline solutions (e.g., or carbonate), forming orange-yellow solutions. It is insoluble in organic solvents like , acetone, and ether, and demonstrates thermal stability up to 250°C before , though it degrades under prolonged exposure to light, oxygen, and reducing agents. In contrast, natural folates display greater chemical lability due to their reduced rings and polyglutamate tails, which render them prone to oxidative cleavage, particularly at acidic (optimal stability above 7) and under heat or light; these forms often require conjugation or stabilization for practical use. Folic acid's oxidized state confers superior stability in fortified foods and pharmaceuticals compared to endogenous folates, facilitating its widespread synthetic application despite requiring enzymatic reduction (via ) for biological activation.

Forms of Folate: Natural vs. Synthetic Folic Acid

Folate naturally occurs in foods primarily as reduced derivatives of tetrahydrofolate (THF), including 5-methyltetrahydrofolate (5-MTHF), 5-formyltetrahydrofolate, and 10-formyltetrahydrofolate, conjugated to multiple glutamate residues forming polyglutamates. These polyglutamate forms require by γ-glutamyl hydrolase enzymes in the intestine for absorption, which can limit to approximately 50% compared to synthetic forms. Natural folates are less stable, susceptible to degradation from heat, light, and storage, resulting in variable content in foods. Synthetic folic acid, or pteroylmonoglutamic acid, is a fully oxidized, monoglutamate form produced industrially for supplements and food fortification. It is absorbed efficiently via both passive diffusion and active transport in the small intestine, achieving bioavailability of 85-100%, higher than natural folates due to direct uptake without deconjugation. Once absorbed, folic acid undergoes reduction by dihydrofolate reductase (DHFR) to dihydrofolate (DHF), then to THF, and ultimately to active forms like 5-MTHF; however, high intakes can saturate DHFR, leading to detectable unmetabolized folic acid (UMFA) in plasma. Key differences include chemical stability, with folic acid resisting breakdown better than natural forms, enabling its use in fortified products like cereals. metrics account for this: dietary folate equivalents (DFEs) adjust synthetic folic acid as 1.7 times more potent than folate when consumed with . Absorption of natural polyglutamates depends on gastrointestinal activity and matrix factors, potentially reducing efficiency in conditions impairing . Metabolically, while both contribute to the folate pool for one-carbon transfers, synthetic folic acid's conversion may be inefficient in individuals with MTHFR polymorphisms, affecting up to 40% of populations and reducing 5-MTHF production. Elevated UMFA from supplements has raised concerns, including masking anemia and potential promotion of progression in some observational studies, though causal evidence remains inconclusive and no definitive adverse effects are established at typical levels. Natural folates, being already reduced, bypass initial reduction steps but provide lower supplemental doses due to constraints.
AspectNatural FolateSynthetic Folic Acid
Chemical FormReduced THF derivatives, polyglutamatesOxidized monoglutamate
StabilityLow (heat/light sensitive)High
Bioavailability~50%85-100%
AbsorptionRequires enzymatic deconjugationDirect, passive/active
MetabolismAlready partially activeNeeds DHFR reduction; risk of UMFA

Biological Functions

Role in DNA Synthesis and Cell Division

Folate, in its active tetrahydrofolate (THF) form, functions as a coenzyme in one-carbon , providing essential one-carbon units for the de novo biosynthesis of and nucleotides required for and repair. Specifically, 10-formyl-THF donates formyl groups for the construction of purine rings in and , while 5,10-methylene-THF serves as the methyl donor in the thymidylate synthase-catalyzed conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), the immediate precursor to the DNA nucleotide deoxythymidine triphosphate (dTTP). This reductive methylation reaction is folate-dependent and consumes THF, regenerating dihydrofolate that must be reduced back by . These processes are indispensable during the of the , where occurs to support chromosomal duplication prior to . disrupts nucleotide pool balance, particularly by limiting dTMP availability, which leads to depletion, uracil misincorporation into nascent strands, and subsequent DNA strand breaks during attempted repair. In rapidly proliferating cells, such as hematopoietic precursors in and , this impairment causes delayed or arrested , with nuclear maturation lagging behind cytoplasmic development. The hallmark clinical consequence is , where ineffective results from apoptotic death of megaloblasts—enlarged, immature erythroid cells with fragmented nuclei—due to stalled . Experimental studies confirm that folate restriction induces defects and specifically during the replicative phase in hematopoietic cells, underscoring folate's causal role in maintaining genomic integrity for ordered . Adequate folate status thus ensures efficient progression through checkpoints, preventing the accumulation of DNA damage that could propagate mutations in daughter cells.

Interaction with Vitamin B12 and One-Carbon Metabolism

Folate and (cobalamin) interact critically within one-carbon metabolism, a network of biochemical pathways essential for reactions, , and . Folate, primarily in the form of tetrahydrofolate (THF) derivatives, serves as a carrier of one-carbon units, facilitating the transfer of in the conversion of to via the enzyme . This enzyme requires , a form of , as a cofactor to accept the methyl group from 5-methyltetrahydrofolate (5-methyl-THF) and transfer it to , regenerating THF for further folate cycle reactions. Disruption of this interaction occurs in , leading to the "methylfolate trap" phenomenon. Without sufficient B12, activity is impaired, causing 5-methyl-THF to accumulate as it cannot donate its effectively. This traps folate in a metabolically inert form, depleting the pool of THF available for other one-carbon transfers, such as thymidylate and synthesis, resulting in a functional despite adequate dietary folate intake. The methylfolate trap explains the overlapping observed in both folate and B12 deficiencies, as impaired affects rapidly dividing cells like erythrocytes. Elevated levels from reduced synthesis further contribute to cardiovascular risks and neurological impairments in B12 deficiency. Experimental evidence from cell studies and observations supports this mechanism, with B12 supplementation restoring folate-dependent pathways.

Biosynthesis, Absorption, and Excretion

Humans lack the genes and enzymes required for de novo folate biosynthesis, rendering it an essential nutrient obtained primarily from the diet, with plants, bacteria, and fungi capable of synthesizing it via a GTP-initiated pathway involving multiple enzymatic steps. Although intestinal bacteria, such as certain Bifidobacterium species, produce folate in the gut, human assimilation of microbially derived folate is limited and insufficient to meet nutritional requirements, as evidenced by studies showing host uptake primarily from the upper small intestine but not compensating for dietary deficiency. Dietary folates exist mainly as reduced polyglutamyl conjugates in foods, which must be hydrolyzed to monoglutamyl forms by brush-border γ-glutamyl hydrolases (conjugases) in the proximal for absorption. Absorption occurs predominantly in the and through two pH-dependent carriers: the proton-coupled folate transporter (PCFT; SLC46A1), which operates optimally at acidic pH (around 5.5) in the proximal jejunum and accounts for most physiological uptake, and the reduced folate carrier (RFC; SLC19A1), active at neutral pH for systemic distribution. Synthetic folic acid, being monoglutamyl and oxidized, is absorbed more efficiently (up to 85-100% ) via these same transporters compared to natural food folates (50% ), followed by rapid reduction and in enterocytes and hepatocytes to 5-methyltetrahydrofolate (5-MTHF), the primary circulating form. Limited colonic absorption of folate occurs via similar mechanisms, potentially contributing during high microbial production, though it represents a minor pathway under normal conditions. An recycles a portion of biliary-excreted folates back to the intestine for reabsorption, aiding retention. Excess folate is excreted primarily via the kidneys, with urinary output of intact folates (mainly 5-MTHF) and catabolites (such as p-aminobenzoylglutamate) increasing proportionally with intake, typically ranging from 50-200 μg/day in adults on adequate diets. Renal reabsorption is mediated by RFC and other transporters in proximal tubules, preventing undue loss, while involves C9-N10 bond cleavage yielding pteridines and p-aminobenzoylglutamates, which are filtered and excreted. Fecal excretion includes unabsorbed dietary residues and minor biliary losses not recycled, with overall folate turnover influenced by status—deficiency reduces and urinary output, while high doses elevate both. In conditions like renal impairment, decreases, potentially altering plasma levels.

Dietary Sources and Intake

Natural Food Sources

Folate, the natural form of vitamin B9, is present in a wide array of and animal foods, with the highest concentrations typically found in leafy green , , and organ meats such as liver. Unlike synthetic folic acid used in , natural folate exists primarily as polyglutamates, which require enzymatic conversion in the gut for absorption, resulting in lower bioavailability compared to the synthetic form. Among , dark leafy greens like provide substantial amounts, with 263 mcg of dietary folate equivalents (DFE) per cup boiled serving, equivalent to 66% of the daily value (DV) for adults. Broccoli offers 168 mcg DFE per cup cooked (42% DV), red bell peppers 68 mcg DFE per cup raw (17% DV), and sweet potatoes approximately 12 mcg DFE per medium baked (3% DV). offers 89 mcg DFE per 4 boiled spears (22% DV), while Brussels sprouts yield 78 mcg DFE per ½ cup boiled (20% DV). Legumes represent another key category, with cooked lentils delivering 179 mcg DFE per ½ cup (45% DV) and black-eyed peas providing 105 mcg DFE per ½ cup (26% DV). Organ meats stand out for their density; beef liver, braised, contains 215 mcg DFE per 3-ounce serving (54% DV), making it one of the most concentrated natural sources. Other animal products like eggs contribute modestly, with one large egg supplying 22 mcg DFE (6% DV). Fruits and nuts offer lower but notable levels; for instance, an provides 81 DFE per half fruit (20% DV), strawberries 36 mcg DFE per cup (9% DV), and yield 68 DFE per ¼ (17% DV). Processing methods affect content, as folate is heat- and water-sensitive; boiling can lead to losses of up to 50-95% in due to leaching, whereas preserves more. The following table summarizes select high-folate foods based on USDA data compiled by the NIH, using DFE per typical serving and % DV (based on 400 DFE for adults):
FoodServing SizeFolate (mcg DFE)% DV
Beef liver, braised3 ounces21554
Lentils, cooked½ cup17945
, boiled1 cup26366
, boiled4 spears8922
, boiled½ cup7820
½ fruit8120
Black-eyed peas, boiled½ cup10526
¼ cup6817
The Recommended Dietary Allowance (RDA) for folate, expressed in dietary folate equivalents (DFE), represents the average daily intake sufficient to meet the nutrient requirements of nearly all (97-98%) healthy individuals in a specific life stage and group, as established by the National Academies of Sciences, Engineering, and Medicine in their Dietary Reference Intakes (DRI). One of folate equals one DFE, while one of synthetic folic from fortified foods or supplements (taken with meals) equals 1.7 DFE, reflecting differences in bioavailability. For infants, Adequate Intake (AI) levels are used due to insufficient data for RDA derivation.
Life Stage GroupRDA or AI (mcg DFE/day)Tolerable Upper Intake Level (UL) for Folic Acid (mcg/day)
Infants 0–6 months65 (AI)Not established
Infants 7–12 months80 (AI)Not established
Children 1–3 years150300
Children 4–8 years200400
Children 9–13 years300600
Adolescents 14–18 years400800
Adults 19+ years4001,000
Pregnancy 14–18 years600800
Pregnancy 19+ years6001,000
Lactation 14–18 years500800
Lactation 19+ years5001,000
The UL applies specifically to synthetic folic acid from supplements and fortified foods, excluding naturally occurring food folate, as high intakes of synthetic forms may mask or lead to unmetabolized folic acid accumulation, whereas natural folate sources do not pose similar risks at equivalent doses. The reaffirmed a UL of 1,000 mcg/day for synthetic folic acid in adults as of 2023, based on evidence that intakes up to this level are unlikely to cause adverse effects in healthy populations. Women capable of becoming pregnant are advised to consume 400 mcg/day of folic acid from supplements or fortified foods, in addition to dietary folate, to reduce risk, though this does not alter the total RDA.

Food Fortification Practices and Debates

Mandatory folic acid fortification of grain products began in the United States in January 1998, when the FDA required the addition of 140 micrograms of folic acid per 100 grams of , , , and to prevent defects (NTDs). Canada implemented a similar program in November 1998, mandating fortification of white , , and at comparable levels. These initiatives targeted women of childbearing age, as folate intake from diet alone often proved insufficient to reduce NTD risk, with post-fortification studies showing a 20-50% decline in NTD incidence in both countries. By 2024, approximately 72 countries had adopted mandatory folic acid policies for or other staples, including (2000, 220 μg/100 g ), , , and , while others like the introduced it in late 2024 for non-wholemeal . In the , voluntary of corn masa flour was permitted in 2016 to address gaps in populations, though uptake remains limited. has demonstrably elevated population folate status, with adults' median serum folate levels rising from 5.1 ng/mL pre- to 11.4 ng/mL by 2004, correlating with reduced NTD prevalence without widespread adverse effects in large cohorts. Debates center on balancing NTD prevention against potential risks, including the masking of , where high folic acid intake corrects but allows undetected neurological damage to progress, particularly in the elderly with rates of B12 deficiency up to 20%. Critics argue contributes to unmetabolized folic acid accumulation in plasma, observed in up to 78% of adults post-fortification at doses exceeding 200 μg/day, potentially disrupting and immune function via inhibition of activity. Some epidemiological data link post-fortification eras to increased late-onset rates in fortified nations, hypothesizing promotion of pre-neoplastic lesions, though causality remains contested and confounded by screening improvements. Proponents emphasize empirical benefits outweighing risks, citing randomized trials and population studies showing no overall cancer increase and fortified intakes rarely exceeding the 1,000 μg/day upper limit except in supplement users. European countries like the and historically resisted mandatory programs due to these concerns, opting for supplementation campaigns, but recent adoption reflects accumulating evidence of NTD reductions without confirmed harm at fortification levels. Ongoing highlights genetic factors, such as MTHFR C677T polymorphisms affecting 10-20% of populations and impairing folic acid conversion, suggesting tailored approaches over universal fortification. Debates persist on optimizing levels to minimize risks while maximizing gains, with calls for monitoring B12 status and considering voluntary models in low-risk groups.

Health Benefits

Prevention of Neural Tube Defects and Birth Outcomes

Folic acid supplementation in the periconceptional period—ideally starting at least one month before conception and continuing through the first trimester—has been shown to reduce the risk of defects (NTDs), including and , by approximately 50% to 70% in randomized controlled trials and meta-analyses. The landmark Council Vitamin Study in 1991 demonstrated that 4 mg daily of folic acid prevented recurrence of NTDs in high-risk women, while subsequent trials confirmed efficacy for primary prevention at lower doses of 0.4 mg daily. The U.S. Preventive Services Task Force recommends that all women capable of becoming pregnant consume 0.4 to 0.8 mg of folic acid daily from supplements, in addition to fortified foods, due to the critical role of folate in closure, which occurs within the first 28 days post-conception. For women with prior NTD-affected pregnancies, doses up to 4 mg daily are advised to achieve greater risk reduction exceeding 70%. Mandatory folic acid of grain products, implemented in , led to a significant decline in NTD , from 1.58 per 1,000 births pre- to 0.86 per 1,000 births afterward, preventing an estimated 1,300 NTD cases annually. Similar reductions of up to 50% have been observed in countries with mandatory programs, contrasting with lesser effects from voluntary or supplementation alone.00543-6/fulltext) Population-level data indicate that increases serum folate levels broadly, addressing gaps in voluntary intake, though residual NTD cases persist due to factors like genetic predispositions or folate-insensitive defects. Beyond NTDs, periconceptional folic acid supplementation is associated with improved birth outcomes, including reduced risks of and . Preconceptional use for one year or more correlates with a 50% to 70% decrease in early spontaneous s (before 34 weeks), though effects on late preterm or induced births are less consistent. Meta-analyses of dietary folate intake show a significant reduction in overall risk, with observational data linking supplementation to lower incidence, potentially through enhanced one-carbon metabolism supporting fetal growth. However, randomized trials yield mixed results for these outcomes, with stronger evidence confined to populations with suboptimal baseline folate status.

Cardiovascular and Anemia Prevention

Folate, a water-soluble B vitamin, plays a critical role in DNA synthesis and red blood cell maturation, with deficiency leading to megaloblastic anemia characterized by ineffective erythropoiesis, macrocytic red blood cells, and hypersegmented neutrophils. Supplementation with folic acid effectively treats folate-deficiency megaloblastic anemia, typically at doses of 1 to 5 mg daily for adults, resulting in normalization of hematologic parameters within days to weeks and raising serum folate levels within 17 days. Guidelines recommend oral folic acid as first-line therapy for confirmed folate deficiency without neurologic symptoms, with monitoring for response via reticulocyte count peaking around day 5-7 and hemoglobin improvement over 1-2 months. Prevention of folate-deficiency anemia relies on adequate dietary intake, with recommendations of at least 400 mcg dietary folate equivalents (DFE) daily—equivalent to about 240 mcg synthetic folic acid—to maintain erythropoiesis in at-risk populations such as those with poor nutrition or malabsorption. Food fortification programs have reduced anemia prevalence in fortified regions by ensuring baseline folate sufficiency, though supplementation is advised for high-risk groups like pregnant individuals or those on folate antagonists. In cardiovascular health, folate facilitates the remethylation of to via the pathway, reducing circulating homocysteine levels—a proposed independent risk factor for , , and coronary events. Folic acid supplementation consistently lowers plasma homocysteine by 20-25% at doses of 0.5-5 mg daily, with greater reductions in individuals with low baseline folate or high homocysteine. However, large randomized controlled trials and meta-analyses have generally failed to demonstrate a reduction in major cardiovascular events, such as or overall CVD mortality, from folate supplementation alone or combined with B6 and B12 in primary or secondary prevention settings. Some evidence suggests subgroup benefits, particularly for reduction in populations with low folate status or in regions without , such as a 2019 reporting a 15% in (RR 0.85, 95% CI 0.77-0.94) among cardiovascular patients receiving folic acid. A 2024 similarly hypothesized cardiovascular risk reduction via lowering, though results were inconsistent across outcomes. High-dose folic acid post-myocardial infarction may lower cardiovascular mortality in select cases, but does not significantly impact recurrent events or overall prognosis. Observational associations between low folate and elevated CVD risk persist, but causal evidence from intervention trials remains limited, prompting caution against routine supplementation for cardiovascular prevention outside deficiency correction.

Cognitive and Neurological Support

Folate contributes to cognitive and neurological health via its essential role in one-carbon metabolism, facilitating , synthesis, and production, including monoamines like serotonin and . Low folate status disrupts these processes, leading to elevated levels that promote and vascular damage in the . Observational studies consistently link to cognitive deficits, with serum levels below 4.4 ng/mL associated with a 1.68-fold higher risk and 2.98-fold increased all-cause mortality in older adults. Even normal-but-low folate concentrations correlate with elevated risks of cognitive disorders and depression in the elderly, independent of other factors. Folate shortfall also exacerbates depressive symptoms, potentially impairing response through impaired of genes regulating mood pathways. Folic acid supplementation yields mixed outcomes for . A 2024 meta-analysis of randomized trials found it improves function in older adults with , particularly by lowering inflammatory cytokines like interleukin-6. Benefits appear more pronounced in those with low baseline folate or vascular risk factors, where it reduces and supports integrity. However, large trials report no prevention of cognitive decline over 3 years, even with B-vitamin combinations. One 2023 analysis suggested isolated folate/folic acid intake may elevate Alzheimer's and risks, possibly due to unmetabolized synthetic forms altering brain structure. Genetic factors modulate these effects; the MTHFR C677T TT genotype impairs folate conversion to active forms, independently raising hyperintensity progression and risk in cerebral small vessel disease patients. Homozygous carriers exhibit reduced gray matter volume and heightened vulnerability to folate-related neurological decline. Overall, while low folate causally contributes to neurological vulnerability via metabolic disruption, supplementation efficacy hinges on baseline status, , and duration, warranting personalized approaches over universal fortification.

Health Risks and Controversies

Masking of Vitamin B12 Deficiency

High doses of folic acid can correct the megaloblastic anemia associated with vitamin B12 deficiency by supporting DNA synthesis in erythroid precursors, thereby masking the hematological manifestation while permitting subacute combined degeneration of the spinal cord and other neurological complications to advance undetected. This phenomenon was first documented in clinical observations from the 1940s and 1950s, when folic acid administration alleviated anemia in patients with pernicious anemia but failed to halt demyelination and neuropathy, sometimes leading to irreversible damage upon delayed B12 diagnosis. The biochemical basis involves overlapping roles in one-carbon metabolism: is required for activity, which regenerates tetrahydrofolate; in its absence, unmetabolized folic acid accumulates and partially compensates for impaired synthesis in , normalizing and levels without addressing neuronal transfer deficits. Experimental animal models and human case reports indicate that this masking delays by 6–12 months on average in affected individuals, exacerbating risks in populations with high B12 , such as the elderly ( of B12 deficiency >15% over age 60) or those with . Some evidence suggests high folic acid may actively accelerate neurological progression rather than merely conceal it, as observed in studies where folate excess worsened and severity during B12 depletion. Food fortification with folic acid, implemented in countries like the since 1998 at 140 μg per 100 g of cereal grains, has raised concerns about population-level masking, potentially affecting 1–5% of older adults with undiagnosed B12 deficiency by elevating serum folate to >20 nmol/L without routine B12 screening. Post-fortification data show no surge in reported neuropathy cases, but critics argue underdiagnosis persists due to reliance on as a sentinel symptom, advocating pre-supplementation B12 assays, especially for doses exceeding μg daily. A 2021 hypothesis posits that excess folic acid depletes circulating holotranscobalamin (active B12 carrier) via renal competition, compounding deficiency in marginal cases, though human trials confirming this mechanism remain limited. Clinical guidelines from bodies like the American Society of Hematology recommend measuring serum B12 (with confirmation if borderline) before initiating folic acid therapy >1 mg/day to mitigate risks, as untreated neurological sequelae include , , and dementia-like symptoms irreversible beyond early intervention. While benefits for prevention (reducing incidence by 20–50%) outweigh masking risks in most analyses, vulnerable subgroups warrant targeted monitoring to prevent iatrogenic harm. Folate plays a critical role in and , processes essential for , leading to a dual influence on : deficiency may initiate tumor formation by causing DNA instability and uracil misincorporation, while excess, particularly from synthetic folic acid supplementation, may accelerate progression of established preneoplastic lesions or tumors by enhancing availability for rapid . Animal models provide mechanistic evidence for promotion; for instance, in a 2017 study using PyMT-induced mice, a high folic acid diet (6 mg/kg) increased total tumor volume by 1.9-fold compared to controls, correlating with elevated plasma folate levels and altered tumor . Similarly, a 2014 study found folic acid supplementation promoted progression, with sentinel tumors showing significantly higher proliferation rates in supplemented groups. Human observational and interventional data reveal inconsistencies, often reflecting timing and context of exposure. A 2009 randomized in patients with ischemic heart disease reported that 0.8 mg/day folic acid plus 0.4 mg/day supplementation over 38 months increased cancer incidence ( 1.21) and mortality ( 1.38) compared to , prompting concerns over promotion in at-risk populations. Meta-analyses of randomized controlled trials yield mixed results: a 2013 analysis of 13 trials (n=52,533) found no overall increase in cancer incidence from folic acid ( 1.07, 95% CI 0.99-1.16), but subgroup analyses hinted at site-specific risks, such as for . Conversely, a 2012 meta-analysis of 10 trials noted a borderline significant elevation in overall cancer frequency ( 1.21, 95% CI 1.00-1.45) with folic acid versus controls. Unmetabolized folic acid (UMFA), detectable in plasma after high-dose supplementation or , has been linked to heightened risk, potentially disrupting one-carbon and favoring aberrant . A 2015 nested case-control study within the (n=329 colorectal cancer cases) found prediagnostic plasma UMFA levels associated with increased risk (odds ratio 1.77 per unit increase, 95% CI 1.15-2.73), independent of total folate, suggesting synthetic forms may exert unique promotional effects absent in natural dietary folate. This aligns with concerns over mandatory ; post-fortification data from regions like the U.S. (since 1998) show no broad cancer surge but potential acceleration in individuals harboring subclinical adenomas, as inferred from rodent models where supraphysiologic doses enhanced lesion progression. Recent reviews emphasize dose-dependency: moderate intake (e.g., 400 μg/day) may protect against initiation, but intakes exceeding 1 mg/day could fuel growth in folate-replete or genetically susceptible individuals, underscoring the need for personalized thresholds over universal supplementation.

Associations with Autism and Developmental Disorders

Prenatal folic acid supplementation, particularly from preconception through early pregnancy, has been associated with a reduced risk of autism spectrum disorder (ASD) in offspring across multiple observational studies and meta-analyses. A 2021 meta-analysis of cohort and case-control studies reported that folic acid use during early pregnancy lowered ASD risk with an odds ratio (OR) of 0.57 (95% CI 0.41–0.78). Similarly, a 2017 meta-analysis found a relative risk (RR) of 0.771 (95% CI 0.641–0.928) for ASD among children of mothers supplementing with folic acid. These protective effects align with folic acid's role in one-carbon metabolism and DNA methylation, processes critical for neurodevelopment, though causality remains unestablished due to observational designs and potential confounders like socioeconomic status or multivitamin use. Conversely, elevated maternal serum folate concentrations during early pregnancy have been linked to increased ASD risk in some cohorts. A 2016 study of 1,391 mother-child pairs found that maternal plasma folate levels ≥60.3 nmol/L at birth were associated with a 2.5-fold higher ASD risk (95% CI 1.3–4.6) compared to levels of 13.5–45.3 nmol/L. A 2020 prospective study in reported that high maternal serum folate (>39.0 nmol/L) in the first trimester correlated with greater ASD occurrence in offspring (adjusted OR 3.99, 95% CI 1.36–11.70). Unmetabolized folic acid (UMFA) in , a marker of excess synthetic folic acid intake exceeding metabolic capacity, showed a dose-dependent association with ASD risk in children (highest quartile OR 3.01, 95% CI 1.16–7.81), but not in other racial groups. These findings suggest a potential U-shaped curve, where deficiency and excess both pose risks, possibly due to disruptions in folate-dependent epigenetic regulation or from unmetabolized forms. Genetic variations in folate metabolism genes, notably methylenetetrahydrofolate reductase (MTHFR) polymorphisms, may modulate these associations. Meta-analyses indicate that the MTHFR C677T variant, which impairs enzyme activity and folate conversion to active 5-methyltetrahydrofolate, elevates ASD susceptibility (pooled OR 1.42 for TT vs. CC ). A 2020 meta-analysis confirmed this link specifically for C677T (OR 1.65, 95% CI 1.28–2.13), while A1298C showed inconsistent or null associations. Individuals with MTHFR variants may accumulate unmetabolized folic acid or exhibit suboptimal , potentially exacerbating neurodevelopmental vulnerabilities; some case reports suggest symptom improvement with methylated folate alternatives like L-methylfolate in affected children. However, high-dose synthetic folic acid may not benefit—and could harm—those with reduced metabolic efficiency, highlighting the need for personalized approaches over universal fortification. Conflicting results across studies underscore methodological challenges, including reliance on self-reported intake, variability in assaying folate forms (e.g., serum total folate vs. UMFA), and ethnic differences in MTHFR prevalence. Protective effects predominate for moderate supplementation (400–600 μg/day), but risks from supraphysiological levels warrant caution, especially post-fortification eras where baseline intakes have risen. Randomized trials are limited, and no causal mechanisms are definitively proven; ongoing research emphasizes measuring bioactive folate species and genetic profiles for risk stratification.

Effects of Unmetabolized Folic Acid and Genetic Variations

Unmetabolized folic acid (UMFA) refers to synthetic folic acid that remains unconverted in the bloodstream after ingestion from fortified foods or supplements, due to saturation of the enzyme (DHFR), which initiates its reduction to active tetrahydrofolate forms. Plasma levels of UMFA are detectable at intakes exceeding 200-400 μg per day, particularly in populations with high consumption of fortified products, and have been observed in and following maternal supplementation. Elevated UMFA has been linked to adverse immunological effects, including reduced cytotoxicity among postmenopausal women, potentially impairing immune surveillance. Studies suggest UMFA may compete with natural reduced folates for cellular uptake and metabolism, disrupting one-carbon transfer processes essential for and repair. This interference raises concerns for increased , , and , though causal mechanisms remain under investigation. In contexts, prediagnostic UMFA levels correlated with higher tumor progression risk, contrasting with protective effects of natural folates. Genetic variations, notably in the MTHFR gene such as the C677T polymorphism, exacerbate UMFA accumulation by impairing the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the primary circulating active form. Ordinary folic acid requires conversion to active 5-MTHF; in variants (especially TT homozygotes) or high doses, some remains unmetabolized as UMFA and accumulates in blood; it is primarily excreted via kidneys in urine, with the liver slowly processing the remainder and some temporarily circulating in blood. Low doses (e.g., 400 mcg from food or supplements) keep UMFA low and harmless; higher doses or severe variants may increase accumulation, with some studies noting potential risks (e.g., immune or tumor effects), but the CDC deems overall safe without confirmed health risks. Homozygous carriers () exhibit up to 70% reduced activity, leading to inefficient folic acid processing and higher UMFA in among supplemented mothers. In these individuals, excess folic acid intake may heighten risks of immune dysregulation, imbalances, and adverse reproductive outcomes like fetal loss, prompting recommendations for alternative folates such as 5-methyltetrahydrofolate over synthetic folic acid. Evidence for these associations derives primarily from observational cohorts, with randomized trials needed to confirm and quantify population-level impacts.

Deficiency States

Causes and Prevalence

Folate deficiency arises primarily from inadequate dietary intake of folate-rich foods such as leafy greens, legumes, and fortified grains, which is exacerbated by overcooking or poor in plant sources. syndromes, including celiac disease, , and , impair intestinal uptake of folate, while chronic alcohol consumption disrupts hepatic storage and , increasing risk by up to 3-4 fold in heavy drinkers. Pharmacological factors, such as long-term use of anticonvulsants (e.g., ), , or , antagonize folate or absorption, often necessitating supplementation. Increased physiological demands during , , infancy, or hemolytic anemias elevate requirements beyond typical intake, with unmet needs leading to rapid depletion due to folate's short tissue stores ( of weeks). Rare congenital causes include hereditary folate malabsorption or defects in folate transport proteins, though these account for a minority of cases compared to acquired factors. Genetic polymorphisms like MTHFR C677T may reduce folate utilization efficiency but rarely cause outright deficiency without dietary or other stressors. Globally, folate deficiency prevalence exceeds 20% among women of reproductive age in low- and middle-income countries lacking mandatory fortification, driven by dietary limitations and high unmet needs in pregnancy. In high-income nations with grain fortification policies, such as the United States and Canada implemented since the late 1990s, population-level deficiency has dropped below 5%, though isolated cases persist in subgroups like alcoholics or the elderly. Among pregnant women, rates vary widely: 0-5% in Europe with supplementation norms, but up to 50% in resource-limited settings like parts of Ethiopia or India. Recent data from unfortified regions, including 77 countries as of July 2023, indicate ongoing public health burdens, with adolescent prevalence reaching 41% in some urban low-socioeconomic groups.

Symptoms, Diagnosis, and Treatment

primarily manifests as due to impaired in erythroid precursors, leading to ineffective . Common symptoms include , weakness, , on exertion, and irritability, often developing gradually as the body compensates through increased production. Gastrointestinal symptoms such as (smooth, red tongue), cheilosis, , and anorexia are frequent, while dermatologic changes like skin and nail abnormalities may occur. Neurological effects, though less prevalent than in , can involve , depression, , and , particularly in chronic cases. In severe or prolonged deficiency, elevated levels contribute to cardiovascular risks, but symptoms alone are nonspecific and overlap with other anemias. Diagnosis relies on laboratory confirmation rather than clinical presentation alone, as symptoms mimic those of or shortage. A typically reveals ( >100 fL), reticulocytopenia, and hypersegmented neutrophils on peripheral smear. Serum folate levels below 3 ng/mL suggest deficiency, though folate (reflecting tissue stores) below 140 ng/mL provides a more reliable assessment, as serum values can fluctuate with recent intake. To distinguish from , measure serum , (elevated only in B12 deficiency), and (elevated in both); concurrent testing prevents misdiagnosis, as folate supplementation can mask B12-related neurological damage. , showing megaloblastic changes, is rarely needed but confirmatory in ambiguous cases. Treatment involves oral folic acid supplementation at 1 mg daily for adults, which rapidly corrects hematologic abnormalities within 1-2 weeks and normalizes folate levels; higher doses (up to 5 mg daily) may be used for or severe cases, with response monitored via repeat blood counts. Dietary augmentation with folate-rich foods like leafy greens, , and fortified grains supports long-term resolution, while addressing underlying causes—such as , syndromes, or medications (e.g., )—prevents recurrence. Vitamin B12 status must be evaluated and supplemented if low before initiating folate therapy to avoid exacerbating subacute combined degeneration. In or hemolytic conditions with increased demand, prophylaxis with 400-800 mcg daily is standard, but therapeutic doses require medical supervision to mitigate risks like depletion from prolonged high intake.

Interactions and Therapeutic Uses

Drug Interactions and Interference

, a (DHFR) inhibitor used in , , and treatment, antagonizes folate by blocking the conversion of dihydrofolate to the active tetrahydrofolate cofactor essential for and methylation reactions, often necessitating (leucovorin) rescue to mitigate toxicity without reducing antitumor efficacy. Similarly, antimicrobial DHFR inhibitors such as trimethoprim (in co-trimoxazole) and impair folate metabolism, potentially inducing during extended therapy, particularly in folate-deficient individuals. Antiepileptic drugs like , , , and lower serum folate levels through mechanisms including reduced intestinal absorption, increased renal clearance, and hepatic enzyme induction that accelerates folate ; conversely, folic acid supplementation can diminish the efficacy of these agents, possibly by enhancing their hepatic or competing for . Sulfasalazine, employed for ulcerative colitis and rheumatoid arthritis, competitively inhibits folate absorption in the jejunum by binding to carrier proteins, leading to subnormal folate status in up to 20-30% of long-term users. Metformin, a first-line antidiabetic, is associated with reduced folate concentrations via interference with intestinal uptake and one-carbon metabolism, though prospective trials show mixed impacts on clinical outcomes like homocysteine levels. Chronic alcohol intake disrupts folate by impairing jejunal absorption, accelerating urinary excretion, and inhibiting hepatic DHFR activity, contributing to higher deficiency rates among heavy drinkers.
Drug ClassExamplesInteraction MechanismClinical Implication
DHFR Inhibitors, Trimethoprim, Block folate activation to tetrahydrofolateFolate ; requires monitoring or supplementation (e.g., leucovorin for )
Antiepileptics, , Reduce folate absorption/; folate may lower drug levelsBidirectional: risk and reduced seizure control with co-administration
Anti-inflammatoriesInhibit intestinal folate transportAbsorption impairment; routine supplementation advised in IBD patients
AntidiabeticsMetforminImpair uptake and Mild folate reduction; monitor in long-term use
Alcohol (chronic)Disrupt absorption, renal handling, and DHFRExacerbated in alcoholics

Role in Chemotherapy and Malaria Treatment

Folate antagonists inhibit key enzymes in the folate metabolic pathway, depriving rapidly dividing cells of essential cofactors for DNA and RNA synthesis, a strategy central to chemotherapy for cancers such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and breast cancer. Methotrexate, a structural analog of folic acid, competitively binds dihydrofolate reductase (DHFR), preventing the conversion of dihydrofolate to tetrahydrofolate, which is required for thymidylate and purine production; this leads to DNA strand breaks and apoptosis in tumor cells. The approach originated in 1947 when aminopterin, the precursor to methotrexate, induced remissions in children with acute leukemia, marking the birth of modern chemotherapy. Methotrexate polyglutamates accumulate intracellularly, enhancing potency and duration of DHFR inhibition, though efflux transporters like ABC transporters can confer resistance. To counteract methotrexate's toxicity to non-malignant cells, which rely on folate for normal proliferation, folinic acid (leucovorin) is co-administered as a reduced folate that bypasses the DHFR blockade, selectively rescuing healthy tissues while maintaining antitumor effects; this "rescue therapy" was established in clinical protocols by the 1950s. High-dose regimens, often exceeding 1 g/m² with leucovorin rescue, achieve cerebrospinal fluid penetration for prophylaxis in , with response rates up to 90% in pediatric cases when combined with other agents. Emerging antifolates, such as pralatrexate, target folate transporters overexpressed in lymphomas, offering improved efficacy in relapsed disease, though resistance via DHFR gene amplification or altered transport remains a challenge. In malaria treatment, antifolates exploit the parasite's dependence on de novo folate synthesis—unlike humans, who salvage folate—by targeting sequential s in the pathway, a tactic developed during screening programs that identified proguanil in 1944. selectively inhibits plasmodial DHFR-thymidylate synthase (DHFR-TS), a bifunctional , halting tetrahydrofolate regeneration and production essential for parasite replication; its against is approximately 0.5 nM, far lower than against human DHFR. Combined with sulfadoxine, which blocks (DHPS) upstream by mimicking para-aminobenzoic acid, the regimen (Fansidar) synergistically depletes folate pools, achieving cure rates over 95% in sensitive strains when introduced in 1970. Resistance to sulfadoxine-pyrimethamine has surged globally since the , driven by point in parasite dhfr (e.g., N86I, S108N) and dhps (e.g., A437G, K540E) genes, reducing to below 50% in many African regions by 2000; this prompted its shift from primary treatment to intermittent preventive therapy in . Newer antifolates like proguanil's cycloguanil continue to inform combination therapies with derivatives, underscoring the pathway's enduring therapeutic value despite evolutionary pressures from widespread use.

Historical Development

Discovery and Early Research

In the late 1920s, British physician Lucy Wills observed high incidences of macrocytic anemia among nutritionally deprived pregnant women in Bombay, India, which did not respond to iron therapy or liver extracts used for pernicious anemia. She conducted clinical trials demonstrating that autolyzed yeast extract, such as Marmite, rapidly reversed the anemia's hematological abnormalities, attributing the effect to an unidentified "hemopoietin" or "Wills factor" distinct from known vitamins. This factor was provisionally linked to dietary deficiencies prevalent in rice-based diets lacking green vegetables, though Wills emphasized empirical response over precise biochemical identification. Parallel efforts during the 1930s, led by researchers like William B. Castle and Watson, corroborated Wills' findings by isolating similar activity from liver and , naming it "factor U" or "Wills factor" for its efficacy in nutritional megaloblastic anemias. These studies differentiated it from extrinsic factor (later ) required for , as Wills factor supported erythrocyte maturation in B12-deficient models but failed to fully resolve neurological symptoms in true cases. Animal assays using chicks and rats with folate-depleting diets refined purification, revealing the factor's concentration in green leafy vegetables—hence the eventual naming from Latin folium (leaf). Folic acid, the synthetic form of folate (pteroylglutamic acid), was first extracted from spinach leaves in 1941 by Herbert K. Mitchell and colleagues at the University of Texas, who obtained a partially purified concentrate active in preventing chick anemia. In 1943, E. L. R. Stokstad's team at Lederle Laboratories achieved the first crystallization of pure folic acid, confirming its structure as a pteridine derivative conjugated to p-aminobenzoic acid and glutamic acid. Chemical synthesis followed in 1945 by Angus Taylor and others, enabling large-scale production and therapeutic trials that demonstrated folic acid's rapid correction of megaloblastic anemias in humans, though its limitations in preventing B12-related subacute combined degeneration were soon evident. Early metabolic studies in the 1940s established its role in one-carbon transfer reactions essential for purine and thymidine synthesis, laying groundwork for understanding folate's biochemical necessity beyond hematopoiesis.

Implementation of Fortification Policies

Mandatory folic acid fortification policies emerged in response to evidence from randomized trials demonstrating that periconceptional folic acid supplementation reduces the incidence of neural tube defects (NTDs). The United States Food and Drug Administration (FDA) issued a final rule on March 5, 1996, requiring fortification of enriched cereal grain products—including flour, breads, rolls, buns, and pasta—with 140 micrograms of folic acid per 100 grams of product, effective by January 1, 1998. Canada implemented a similar mandate in 1998, targeting white flour, enriched cornmeal, and pasta at comparable levels to achieve population-wide intake increases without relying on voluntary supplementation. Following these precedents, several countries in adopted mandatory fortification of . Chile began fortifying all with 220 micrograms of folic acid per 100 grams in late 2000, aiming to address high baseline NTD rates. and initiated programs in the late , while , , and followed in the early 2000s, often aligning fortification levels to deliver approximately 100-240 micrograms daily from staple consumption. In regions where is a dietary staple, policies adapted to include maize flour or meal, as in parts of and . By 2023, 69 countries had enacted mandatory folic acid , predominantly of and flours, while 47 permitted voluntary and 77 had no policies.00543-6/fulltext) The endorses of staple foods as a cost-effective strategy to prevent and NTDs, recommending levels sufficient to increase average daily intake by 100-400 micrograms for women of reproductive age. Implementation varies by context: high-income nations often fortify processed grains, whereas low- and middle-income countries prioritize industrially milled staples to ensure broad coverage without behavioral changes.00378-3/fulltext) In , adoption lagged due to reliance on supplementation campaigns, but the mandated of non-wholemeal in 2021, effective from 2022.
Country/RegionYearPrimary Foods FortifiedTypical Level (μg/100g)
1998Enriched cereal grains140
1998Flour, , 150 ()
2000220
/2009Bread-making 200-300
Challenges in include ensuring compliance among millers, monitoring overages to avoid excessive , and adapting to local diets, such as voluntary maize fortification in where enforcement is limited. The 2023 World Health Assembly resolution urged accelerated adoption of mandatory fortification to address persistent global NTD burdens.

Folate in Non-Human Organisms

In Animals and Veterinary Applications

Folate, a B critical for one-carbon and synthesis, is required in the diets of most non-ruminant animals, which lack the capacity for at levels sufficient for optimal health. In species such as pigs and , dietary supplementation with folic acid is standard in commercial feeds to meet requirements ranging from 0.3–1.3 mg/kg for pigs and 0.25–1.0 mg/kg for , supporting growth, reproduction, and immune function. Studies in laying hens demonstrate that folic acid absorption occurs efficiently in the intestine, with supplementation modulating cecal to enhance microbial diversity and potentially improve production. In ruminants like and sheep, microorganisms synthesize folate, reducing overt dietary needs, yet supplementation during high-demand periods—such as or heat stress—yields measurable benefits. For dairy cows, folic acid combined with improves milk yield and composition by up to 5–10% in early , while in , rumen-protected forms enhance feed efficiency and liver folate status without altering blood metabolites significantly. Excessive supplementation risks inducing B12 deficiency due to metabolic interactions, necessitating balanced dosing. Veterinary applications include treating folate-responsive s and congenital defects in companion animals. In dogs, particularly breeds prone to cleft / like pugs and chihuahuas, oral folic at 5 mg daily during gestation reduces incidence by supporting embryonic development, though it does not consistently lower stillbirths or umbilical hernias. For parvovirus-induced in dogs, supplementation improves hematological parameters including counts and levels. In cats and small dogs with low serum folate, veterinarians recommend 200 mcg daily for 4 weeks, escalating to 400 mcg for larger dogs, often alongside diagnostics for . Aquatic species tolerate folic acid supplementation safely to fulfill nutritional gaps, though maximum safe levels remain unestablished pending further data on long-term exposure. Overall, while microbial synthesis mitigates needs in herbivores, targeted veterinary use underscores folate's role in mitigating stress, enhancing productivity, and addressing species-specific deficiencies.

In Plants, Bacteria, and Industrial Production

Plants synthesize folates de novo through a multi-step pathway comprising 11 enzymatic reactions that assemble the core tetrahydrofolate (THF) structure from (GTP), p-aminobenzoic acid (PABA), and precursors. This is compartmentalized across plastids (for early pterin branch steps), mitochondria (for PABA synthesis from chorismate), and the (for final assembly and polyglutamylation), enabling efficient cofactor production for one-carbon (C1) metabolism essential to , , and pantothenate synthesis. Folate levels in plants are highest in photosynthetic tissues like leaves, where they support metabolic demands, but lower in non-green parts such as roots and seeds, influencing their nutritional value as dietary sources for herbivores and humans. Bacteria, including many prokaryotic species across phyla, possess a conserved de novo folate biosynthesis pathway similar to that in plants, involving GTP cyclohydrolase I for pterin formation, PABA synthase for the aminobenzoate branch, and dihydrofolate synthase for THF assembly. Gut-associated bacteria like Bifidobacterium species and select Lactobacillus strains actively produce folates, exporting forms such as 5-methyl-THF or intermediates like PABA and 6-methylpterin, which can influence host nutrition despite variable bioavailability. This microbial synthesis supports probiotic applications and ecosystem C1 transfer, with production modulated by environmental factors like pH, carbon sources, and inhibitors such as sulfasalazine. Industrial production of folic acid (the synthetic oxidized form of folate) relies primarily on multi-step chemical synthesis, starting from precursors like 2,5-diamino-6-hydroxypyrimidine or guanidine for the pteridine ring, coupled with PABA and L-glutamic acid via reactions including nitration, reduction, and condensation under harsh conditions such as high temperatures and acidic media. Yields have improved through optimized catalysis, but the process generates waste and requires purification to achieve pharmaceutical-grade purity exceeding 98%. Microbial alternatives, including fermentation with engineered Ashbya gossypii or generally recognized as safe (GRAS) bacteria like Bacillus subtilis, have achieved titers up to several grams per liter in lab-scale bioreactors by overexpressing pathway genes and optimizing media, yet chemical synthesis dominates commercial output due to cost and scalability advantages as of 2023. These biotechnological efforts prioritize sustainability, reducing reliance on petrochemical inputs while leveraging renewable feedstocks like glucose.

References

  1. https://.ncbi.nlm.nih.gov/compound/Folic-Acid
  2. https://www.sciencedirect.com/[science](/page/Science)/article/pii/S1751731123001301
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.